Psychedelica in

Psychiatrie and

Psychotherapie

{{ brizy_dc_image_alt uid='wp-2363cffda42f9ba11612e632adf9b7c4' }}

Interdisciplinary Conference on

Psychedelic Research

Exclusief ééndaags symposium voor Nederlandse ggz-professionals

24 April 2020 | Haarlem, The Netherlands

Wat?

An international symposium featuring many of the world’s leading experts in psychedelic research and therapy.

Voor wie?

Psychiatrists, GZ psychologists, psychotherapists, clinical psychologists, addiction doctors, and other BIG-registered professionals in the Netherlands.

Details

Where?

Philharmonie, Haarlem

More info here.

When?

Friday 24 April, 2020.

09:30 – 18:00

Accreditatie

Continuing (medical) education 9 points (FGzPt). 6 points (VVGN, KNMG, NVvP).

More information here.


There is a growing body of evidence suggesting that psychedelics can be used safely and effectively to treat mental disorders, including depression, PTSD, and substance use disorders.

During this one-day symposium, leading psychiatrists, psychotherapists, neuroscientists, and psychopharmacologists in the field of psychedelic-assisted therapies will share the latest scientific developments and insights into the therapeutic use of psychedelics, and discuss the future of treatment and research with MDMA, psilocybin, LSD and other compounds.

This state-of-the-art symposium will showcase the latest clinical evidence on psychedelics in the treatment of mental disorders and will facilitate in-depth interaction and discussion.

Chairs

Prof. dr. Eric Vermetten (LUMC)

Prof. dr. Robert Schoevers (UMCG)

Dr. Metten Somers (UMC Utrecht)

Prof. dr. Wim van den Brink (AUMC).

CME Credits

VVGN (Dutch Association for Addiction Medicine) 6 points

KNMG (Royal Dutch Medical Association) 6 points

FGzPt (Dutch Federation of Healthcare Psychologists and Psychotherapists) 9 points

NVvP (Dutch Association for Psychiatry) 6 points


Tickets

This is a separate symposium aimed to inform and educate healthcare professionals in the Netherlands. You will need a BIG registration number to register. Attendees of ICPR 2020 don’t need to worry, as all speakers will also present during the three days of ICPR 2020.

A limited amount of tickets is available. Price is €295.

For a surplus of €150, attendees can also attend Saturday and Sunday of the Interdisciplinary Conference on Psychedelic Research. A few discounted tickets are available for AIOs, resident psychiatrists in GZ-psychologists in training, at €175.


CONFIRMED ISPPP SPEAKERS

{{ brizy_dc_image_alt uid='wp-aa5f337ce0b27d38c06fba989c5fadce' }}
MATTHEW JOHNSON

Johns Hopkins University

{{ brizy_dc_image_alt uid='wp-4e9f00253a9c0d9a361c3c6c38529ad4' }}
ALICIA DANFORTH

University of California, San Francisco

{{ brizy_dc_image_alt uid='wp-23e30056ecbb7d8d5197ed296b4acbd6' }}
MICHAEL MITHOEFER

Multidisciplinary Association for Psychedelic Studies

{{ brizy_dc_image_alt uid='wp-6f0a6e7b8ebc3cc08534ccd424b70e89' }}
ALEXANDER BELSER

Yale University; New York University

{{ brizy_dc_image_alt uid='wp-ada5d333e74d69bda1920a6986e41929' }}
BEN SESSA

Imperial College London

{{ brizy_dc_image_alt uid='wp-a124eeb6dc15feef58f79b7681ee2776' }}
MICHELLE BAKER JONES

Imperial College London

{{ brizy_dc_image_alt uid='wp-10c0c054fc10dc5c270e2783d21aefd7' }}
MATTHIAS LIECHTI

University Hospital Basel

{{ brizy_dc_image_alt uid='wp-fea26dbbe83f9f0f469cb5fc4bdea3e9' }}
KATRIN PRELLER

University of Zurich

{{ brizy_dc_image_alt uid='wp-24ea008b2132181381cdd5a3d6c9478a' }}
ELIZABETH NIELSON

NYU; Columbia University

{{ brizy_dc_image_alt uid='wp-e6800e2dcd8f70d5850da78dafcc732a' }}
PETER GASSER

Private Practice

{{ brizy_dc_image_alt uid='wp-ac375721f25796ca3c701ebd4c364e1b' }}
JEFFREY GUSS

NYU School of Medicine

{{ brizy_dc_image_alt uid='wp-6b8b9425b80531c29ce3cfb082306a74' }}
TORSTEN PASSIE

Hannover Medical School

{{ brizy_dc_image_alt uid='wp-07699fdd439ff37c87482b7aac74fdaa' }}
MENDEL KAELEN

Wavepaths

Some of the questions that will be discussed at ISPPP

  • What skills, competencies and knowledge do therapists need and how do we train them?
  • What do we know about the neuro-biological and psychological working mechanisms of these substances?
  • What is the role of treatment context, music, and integration sessions in establishing (long-term) clinical outcomes?
  • Can psychedelic-assisted treatments be integrated into conventional mental health care infrastructures?
  • Can we apply conventional psycho-therapeutic methods to psychedelic-assisted therapies or are novel methods needed?

TICKETS AVAILABLE

A limited number of tickets is now available for this exclusive one-day symposium

Regular

AIOS Discount

Combi: ISPP + ICPR (Sat & Sun)

€ 295

€ 175

€ 445

PROGRAMME

Room 3

Overview of working mechanisms & research

09:40 AM – 10:05 AM

Clinical studies with LSD and MDMA in healthy subjects and patients

Matthias Liechti, MD PhD

10:05 AM – 10:30 AM

Psychedelics as behavior change agents

Matthew Johnson, PhD

Clinical applications of MDMA

 10:30 AM – 10:50 AM

MDMA-assisted psychotherapy for PTSD

Michael Mithoefer, MD

10:50 AM – 11:05 AM

MDMA-assisted psychotherapy for social anxiety in autistic adults

Alicia Danforth, PhD

11:05 AM – 11:20 AM

MDMA-assisted psychotherapy for alcoholism

Ben Sessa, MD


Coffee Break


Clinical applications of psilocybin

11:50 AM – 12:05 PM

Psilocybin-assisted treatment of alcohol use disorder

Elizabeth Nielson, PhD

12:05 – 12:20

Psilocybin-assisted psychotherapy for the treatment of end-of-life distress

Alex Belser, PhD

12:20 – 12:50

Patient and therapist perspectives from a psilocybin for depression trial

Michelle Baker-Jones + Matt Jackson


Lunch Break


Psychedelic-assisted psychotherapy: clinical experience and observations

14:20 – 14:40

The development of psycholytic / psychedelic therapy

Peter Gasser, MD

14:40 – 15:00

Low-dose psycholytic therapy: A neglected approach?

Torsten Passie, MD PhD

15:00 – 15:50

Panel: competencies, skills and training of future therapists


Coffee Break


Working mechanisms and setting

16:20 – 16:35

Biological and psychological working mechanisms of psychedelics and entactogens

Katrin Preller, PhD

16:35 – 16:50

The therapeutic value of ayahuasca for transformative mental healthcare

Milan Scheidegger MD, PhD

16:50 – 17:05

Music and setting in psychedelic-assisted therapy

Mendel Kaelen, PhD

17:05 – 17:20

The use of ACT in psilocybin-assisted therapy of major depressive disorder

Jeff Guss, MD

Closing Panel

17:30 – 18:15

Integrating psychedelics into mainstream mental health care

NEWSLETTER

STAY IN TOUCH

Be the first to learn about the ticket sale, speaker announcements and all things ICPR.

{{ brizy_dc_image_alt uid='wp-b4a168891229e58f886492636d8022c8' }}